- The Wall Street Journal•last month
Multinationals operating in China are facing new delays in recent weeks, as Chinese regulators impose tougher restrictions on the movement of capital out of the country to slow the yuan’s decline.
- Reuters•2 months ago
Actelion's silence speaks volumes to the dozens of event-driven hedge funds piling into the Swiss biotech firm, betting that Johnson & Johnson's (J&J) approach will result in an outright takeover and handsome returns. A source familiar with the matter has told Reuters the two companies are discussing a bid of close to $27 billion, or 250 Swiss francs ($248) per share, which is 25 percent above Actelion's current share price. Both companies have confirmed that U.S. diversified healthcare group J&J - maker of Pizbuin sun screen, surgical tools and arthritis drug Remicade - has approached Actelion about a potential takeover, but kept mum on details.
- Reuters - UK Focus•3 months ago
European equities fell for a sixth straight session on Monday, with energy shares tracking weaker crude oil prices and financial stocks losing ground. Europe's STOXX 600 fell 0.5 percent, ending its second ...
SGO.PA: Summary for SAINT GOBAIN - Yahoo Finance
Compagnie de Saint-Gobain S.A. (SGO.PA)
Paris - Paris Delayed price. Currency in EUR
Add to watchlist
|Bid||38.50 x 3900|
|Ask||39.66 x 2600|
|Day's range||45.36 - 46.85|
|52-week range||31.47 - 46.85|
|PE ratio (TTM)||19.45|
|Dividend & yield||1.41 (2.90%)|
|1y target est||N/A|